Home
Latest
E-paper
Companies
Industry
Economy
Blueprint
Finance
Markets
Budget
India News
Politics
External Affairs Defence Security
World News
Opinion
Technology
Immigration
Specials
Partner Content
Sports
Cricket
Lifestyle
Entertainment
Social Viral
Health
BS Decoded
Books
Education
Newsletters
Web Stories
BS at 50
Multimedia
Sudoku
Crossword
BS Apps
Management
Premium
Indulgence
Explore Business Standard
BFSI Insight Summit
Events
About Us
BS Support
Popular Search
India's first off-the-shelf cell therapy treatment for knee osteoarthritis
One injection will cost Rs 1.25 lakh with effects lasting for two years or more
Stempeutics gets DCGI nod for Phase 3 trial to treat Covid patients
Stempeutics said it has received DCGI clearance to conduct Phase 3 clinical trial on its product for treating COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).
Cipla partner Stempeutics gets DCGI nod for stem cell-based product
The company's goal is to globalise its product, Stempeucel, for Buerger's Disease, the company's CEO said
